ZPR1 Inhibitors
ZPR1 Inhibitors are chemical compounds that serve to diminish the activity of ZPR1, a zinc finger protein involved in cellular processes regulated by specific signaling pathways, particularly those connected to Akt and mTOR signaling. One such inhibitor is Perifosine, which reduces ZPR1 activity by inhibiting Akt, thereby decreasing the phosphorylation that ZPR1 requires for its function. Similarly, Triciribine, MK-2206, and GSK690693 are Akt inhibitors that lead to reduced ZPR1 activity through the same mechanism of Akt pathway inhibition.
Besides Akt inhibitors, compounds that target the mTOR pathway also play a role in inhibiting ZPR1. Rapamycin, for instance, is an mTOR inhibitor that disrupts mTORC1 and can decrease ZPR1 activity due to the protein's association with cellular processes governed by mTORC1. OSI-027, AZD8055, PP242, and Torin 1 are additional mTOR inhibitors that indirectly lead to decreased ZPR1 activity by targeting both mTORC1 and mTORC2 complexes. These inhibitors, by halting mTOR signaling, can reduce the activity of ZPR1, which is implicated in the cascade of events downstream of mTOR activation. Wortmannin and LY294002 add another layer of complexity as PI3K inhibitors, which by curtailing the PI3K/Akt signaling pathway, indirectly lead to reduced ZPR1 activity.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Perifosine is an alkylphospholipid that inhibits Akt signaling. ZPR1 is a zinc finger protein whose activity is modulated by Akt-dependent phosphorylation. Perifosine's inhibition of Akt leads to a reduction in ZPR1 activity due to decreased phosphorylation. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is a specific Akt inhibitor that prevents its activation and subsequent phosphorylation of downstream targets. As ZPR1 activity can be regulated by Akt-mediated phosphorylation, Triciribine can decrease ZPR1 activity by inhibiting Akt signaling. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
MK-2206 is an allosteric Akt inhibitor. By inhibiting Akt, MK-2206 can reduce the phosphorylation and activity of ZPR1, as Akt is a known regulator of ZPR1 through its phosphorylation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can inhibit the mTORC1 complex, which is involved in regulating protein synthesis and cellular growth. As ZPR1 is associated with these processes, inhibition by Rapamycin can lead to decreased ZPR1 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor that prevents the activation of Akt. Since ZPR1 activity is influenced by Akt signaling, Wortmannin can lead to decreased ZPR1 activity by inhibiting the upstream PI3K/Akt pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that prevents phosphorylation and activation of Akt. Inhibition of PI3K/Akt signaling by LY294002 results in decreased activity of ZPR1, which is dependent on the Akt pathway for its function. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693 is an ATP-competitive inhibitor of Akt. By inhibiting Akt activity, GSK690693 decreases the phosphorylation and functional activity of ZPR1, which relies on Akt-mediated signals. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
Palomid 529 is a dual TOR/PI3K inhibitor, impacting pathways crucial for cell growth and survival. By inhibiting these pathways, Palomid 529 can decrease ZPR1 activity, which is connected to these cellular processes. | ||||||
OSI-027 | 936890-98-1 | sc-364557 sc-364557A | 10 mg 50 mg | $437.00 $1186.00 | 1 | |
OSI-027 is a selective mTOR inhibitor that can disrupt both mTORC1 and mTORC2 complexes. As ZPR1 is linked to the mTOR pathway, OSI-027 can inhibit ZPR1 activity by inhibiting mTOR signaling. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an mTOR kinase inhibitor that affects both mTORC1 and mTORC2 complexes. Inhibition of mTOR signaling by AZD8055 can lead to decreased ZPR1 activity, as ZPR1 functions are associated with mTOR pathways. | ||||||